PharmTech News

Articles

Gilead’s antiviral drug Veklury is the first approved treatment in the US for COVID-19.

FDA Approves Remdesivir for Hospitalized Patients

200 employees will be hired by the end of 2020, with 300 more planning to be hired by 2023. 

Roche Canada to Invest $500 Million and Create 500 New Jobs at its Canadian Global Pharma Technical Operations Site

Regeneron will distribute Inmazeb treatment doses over the course of six years to BARDA.

FDA Approves Regeneron’s Inmazeb as the First Treatment for Ebola

Roche will use Dyno’s CapsidMap platform to develop next-generation adeno-associated virus vectors for gene therapies for central nervous system diseases and liver-directed therapies. 

Roche and Dyno Therapeutics to Enter into $1.8 Billion Collaboration 

The companies are entering into an agreement for the late-stage development and large-scale manufacturing of AZD7442, AstraZeneca’s investigational product for treatment and prevention of COVID-19.

HHS, DoD, AstraZeneca Enter into $486-Million Agreement for COVID-19 Investigational Product

Through the acquisition, Bristol Myers Squibb will gain access to MyoKardia’s mavacamten, a cardiovascular drug for the treatment of obstructive hypertrophic cardiomyopathy, a chronic heart disease.



Bristol Myers Squibb to Acquire MyoKardia for $13.1 Billion

The acquisition will give Sanofi access to Principia’s Bruton tyrosine kinase inhibitors for its portfolio of next-generation transformative treatments for autoimmune diseases.

Sanofi Completes $3.68-Billion Acquisition of Principia Biopharma

Samsung will offer large-scale commercial manufacturing for drug substance and drug products to support AstraZeneca’s biologics therapeutics capabilities in the Asia-Pacific region.

AstraZeneca and Samsung Biologics to Enter into Long-Term Supply Agreement for Up to $545.6 Million

Roche will gain full rights to Inflazome’s portfolio which includes clinical and preclinical orally available small molecule NLRP3 inhibitors.

Roche Closes Agreement with Inflazome for $450 Million

Valneva will supply the UK government with an initial 60 million doses of the vaccine in the second half of 2021, if successful, and will provide more doses thereafter. 

Top News